Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from IM Cannabis Corp ( (TSE:IMCC) ).
In January 2025, IM Cannabis Corp. made significant changes, including a shift in auditors from Kost Forer Gabbay & Kasierer to Fahn Kanne & Co. Grant Thornton Israel, and the relaunch of high-THC cannabis strains in Israel. The company faced an administrative petition concerning cannabis imports from Canada, which local growers withdrew without imposing costs. The firm is navigating challenges such as global inflation, supply chain disruptions, and geopolitical tensions, including the war between Hamas and Israel, impacting their operations. Regulatory reforms in Israel could potentially improve the accessibility of medical cannabis, offering medium to long-term benefits.
More about IM Cannabis Corp
IM Cannabis Corp. is an Israel-based company operating in the cannabis industry, focusing on medical cannabis distribution and retail segments within Israel. The company is also pursuing market expansion in Europe, particularly through strategic investments and agreements in Germany via its subsidiary, Adjupharm GmbH.
YTD Price Performance: -7.02%
Average Trading Volume: 96,257
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.57M
Learn more about IMCC stock on TipRanks’ Stock Analysis page.
